![Christopher Kenney](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Förmögenhet: 426 685 $ per 2026-06-30
Christopher Kenney is currently the Chief Medical Officer at Xenon Pharmaceuticals, Inc. He previously held positions as the Senior Vice President-Medical Affairs at Acorda Therapeutics, Inc. from 2018 to 2019, the Chief Medical Officer at Cadent Therapeutics, Inc. from 2019 to 2020, and the Senior Vice President-Clinical Development at Biotie Therapies LLC from 2013 to 2016.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
| 2026-04-07 | 7 069 ( 0,01 % ) | 426 685 $ | 2026-06-30 |
| Företag | Position | Start |
|---|---|---|
| XENON PHARMACEUTICALS INC. | Teknisk/Vetenskaplig/F&U Direktör | 2021-08-23 |
| Företag | Position | Slut |
|---|---|---|
Cadent Therapeutics, Inc.
 Cadent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders | Teknisk/Vetenskaplig/F&U Direktör | 2020-12-01 |
| ACORDA THERAPEUTICS, INC. | Teknisk/Vetenskaplig/F&U Direktör | 2019-01-01 |
Biotie Therapies, Inc. | Teknisk/Vetenskaplig/F&U Direktör | 2016-01-01 |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 4 |
|---|---|
Acorda Therapeutics, Inc.
 Acorda Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops neurology therapies | Health Technology |
Xenon Pharmaceuticals, Inc.
 Xenon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovering, developing and delivering of therapeutics for neurological & psychiatric disorders | Health Technology |
Cadent Therapeutics, Inc.
Cadent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders | Health Technology |
Biotie Therapies, Inc. |
Välj din utgåva
All finansiell information anpassad till den nationella nivån
